Graphite Bio, South San Francisco, CA, USA.
Nat Commun. 2024 Mar 23;15(1):2625. doi: 10.1038/s41467-024-46816-5.
Homology Directed Repair (HDR) enables precise genome editing, but the implementation of HDR-based therapies is hindered by limited efficiency in comparison to methods that exploit alternative DNA repair routes, such as Non-Homologous End Joining (NHEJ). In this study, we develop a functional, pooled screening platform to identify protein-based reagents that improve HDR in human hematopoietic stem and progenitor cells (HSPCs). We leverage this screening platform to explore sequence diversity at the binding interface of the NHEJ inhibitor i53 and its target, 53BP1, identifying optimized variants that enable new intermolecular bonds and robustly increase HDR. We show that these variants specifically reduce insertion-deletion outcomes without increasing off-target editing, synergize with a DNAPK inhibitor molecule, and can be applied at manufacturing scale to increase the fraction of cells bearing repaired alleles. This screening platform can enable the discovery of future gene editing reagents that improve HDR outcomes.
同源定向修复 (HDR) 可实现精确的基因组编辑,但与利用非同源末端连接 (NHEJ) 等替代 DNA 修复途径的方法相比,HDR 的效率有限,这限制了基于 HDR 的疗法的实施。在这项研究中,我们开发了一种功能性的、组合式筛选平台,以鉴定可提高人造血干细胞和祖细胞 (HSPC) 中 HDR 的蛋白试剂。我们利用该筛选平台探索 NHEJ 抑制剂 i53 与其靶标 53BP1 的结合界面的序列多样性,确定了可形成新的分子间键并能显著提高 HDR 的优化变体。我们表明,这些变体特异性地减少插入缺失结果,而不会增加脱靶编辑,与 DNA 蛋白激酶抑制剂分子协同作用,并可在制造规模上应用以增加携带修复等位基因的细胞比例。该筛选平台可用于发现提高 HDR 结果的未来基因编辑试剂。